ArticleBiomaterials2013
Peptide targeted tripod macrocyclic Gd(III) chelates for cancer molecular MRI.
Article in Biomaterials, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 82 citations in OpenAlex.
- Visualizing the Tumor Microenvironment: Molecular Imaging Probes Target Extracellular Matrix, Vascular Networks, and Immunosuppressive Cells.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Peptide-Based Agents for Cancer Treatment: Current Applications and Future Directions.International journal of molecular sciences · 2023Review
- Recent advances of CREKA peptide-based nanoplatforms in biomedical applications.Journal of nanobiotechnology · 2023Review
- Fibrin-Targeted Nanoparticles for Finding, Visualizing and Characterizing Blood Clots in Acute Ischemic Stroke.Pharmaceutics · 2022Article
- Integrin α6-Targeted Magnetic Resonance Imaging of Hepatocellular Carcinoma in Mice.Molecular imaging and biology · 2020Article
- Fibronectin-targeted dual-acting micelles for combination therapy of metastatic breast cancer.Signal transduction and targeted therapy · 2020Article
- Chemokine receptor 4 targeted protein MRI contrast agent for early detection of liver metastases.Science advances · 2020Article
- Fibrin-Targeted Polymerized Shell Microbubbles as Potential Theranostic Agents for Surgical Adhesions.Langmuir : the ACS journal of surfaces and colloids · 2019Article
- Chemistry of MRI Contrast Agents: Current Challenges and New Frontiers.Chemical reviews · 2019Review
- Effective MR Molecular Imaging of Triple Negative Breast Cancer With an EDB-Fibronectin-Specific Contrast Agent at Reduced Doses.Frontiers in oncology · 2019Article
- Synthesis and Preclinical Evaluation of the Fibrin-Binding Cyclic PeptideContrast media & molecular imaging · 2019Article
- Magnetic resonance molecular imaging of metastatic breast cancer by targeting extradomain-B fibronectin in the tumor microenvironment.Magnetic resonance in medicine · 2018Article
- Evaluation of methotrexate-conjugated gadolinium(III) for cancer diagnosis and treatment.Drug design, development and therapy · 2018Article
- Synthesis and Assessment of Peptide Gd-DOTA Conjugates Targeting Extradomain B Fibronectin for Magnetic Resonance Molecular Imaging of Prostate Cancer.Molecular pharmaceutics · 2017Article
- Targeted gadofullerene for sensitive magnetic resonance imaging and risk-stratification of breast cancer.Nature communications · 2017Article
- Magnetic resonance molecular imaging for non-invasive precision cancer diagnosis.Current opinion in biomedical engineering · 2017Article
- EDB Fibronectin-Specific SPECT ProbeACS omega · 2017Article
- Targeted Contrast Agent Specific to an Oncoprotein in Tumor Microenvironment with the Potential for Detection and Risk Stratification of Prostate Cancer with MRI.Bioconjugate chemistry · 2017Article
- Targeting Fibronectin for Cancer Imaging and Therapy.Journal of materials chemistry. B · 2017Article
- Design, synthesis, and evaluation of VEGFR-targeted macromolecular MRI contrast agent based on biotin-avidin-specific binding.International journal of nanomedicine · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
Rational design and develop of targeted contrast agents binding to cancer-related proteins will achieve more accurate cancer diagnosis and prognosis by magnetic resonance (MR) imaging. CREKA is a tumor-homing pentapeptide (Cys-Arg-Glu-Lys-Ala) specifically homes to fibrin-fibronectin complexes abundantly expressed in tumor microenvironment. In this study, we developed and evaluated a CREKA peptide targeted multiplexed Gd-MR probe (CREKA-Tris-Gd(DOTA)3) for MR imaging of breast tumors. CREKA and azide bearing Gd(III) was attached to a maleimide-functional trialkyne scaffold via thiol-maleimide and azide-alkyne click chemistry, respectively. CREKA-Tris-Gd(DOTA)3 has a well-defined structure with a molecular weight of 2914 Da. The T1 relaxivity of CREKA-Tris-Gd(DOTA)3 is 8.06 mM(-1) s(-1) per Gd (24.18 mM(-1) s(-1) per molecule) at room temperature and 3 T. Fluorescence imaging showed high binding specificity of CREKA to a 4T1 breast tumor model in mice while it was not found for the scrambled CREKA (CERAK). The CREKA peptide-targeted contrast agent resulted in greater contrast enhancement than the corresponding CERAK agent and the commercialized contrast agent ProHance(®) in tumor at a dose of 0.1 mmol Gd/kg in female athymic mice bearing 4T1 breast carcinoma xenograft. This small molecular contrast agent was easily excreted from body after imaging indicated low toxicity. The targeted MRI contrast agent has a potential for specific cancer molecular imaging with MRI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.